Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Guardant Health, Inc. (NASDAQ:GH) has been assigned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $39.27.

Several analysts recently weighed in on GH shares. TD Cowen lifted their price objective on Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Citigroup boosted their price target on shares of Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Stephens reiterated an “overweight” rating and set a $44.00 price objective on shares of Guardant Health in a research note on Friday, May 24th. Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. Finally, JPMorgan Chase & Co. increased their target price on Guardant Health from $45.00 to $48.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $27.95 on Tuesday. The firm’s 50 day simple moving average is $30.62 and its 200-day simple moving average is $24.24. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95. Guardant Health has a one year low of $15.81 and a one year high of $41.06. The firm has a market cap of $3.42 billion, a PE ratio of -7.13 and a beta of 1.13.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The firm had revenue of $177.24 million for the quarter, compared to analysts’ expectations of $162.59 million. Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.67) earnings per share. As a group, equities analysts predict that Guardant Health will post -3.31 EPS for the current year.

Institutional Trading of Guardant Health

Several large investors have recently bought and sold shares of GH. Quarry LP acquired a new position in shares of Guardant Health in the second quarter valued at about $44,000. Manchester Capital Management LLC purchased a new stake in Guardant Health in the first quarter valued at approximately $57,000. Canton Hathaway LLC acquired a new position in Guardant Health in the 2nd quarter worth approximately $59,000. Headlands Technologies LLC raised its position in Guardant Health by 362.3% during the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after buying an additional 1,844 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Guardant Health during the 2nd quarter valued at approximately $71,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.